David Hochman - Orchestra BioMed Chairman Founder
| OBIO Stock | 5.34 0.01 0.19% |
Chairman
David Hochman is Chairman Founder of Orchestra BioMed Holdings
| Age | 49 |
| Address | 150 Union Square Drive, New Hope, PA, United States, 18938 |
| Phone | 212 862 5797 |
| Web | https://orchestrabiomed.com |
David Hochman Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Hochman against Orchestra BioMed stock is an integral part of due diligence when investing in Orchestra BioMed. David Hochman insider activity provides valuable insight into whether Orchestra BioMed is net buyers or sellers over its current business cycle. Note, Orchestra BioMed insiders must abide by specific rules, including filing SEC forms every time they buy or sell Orchestra BioMed'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Hochman over a month ago Acquisition by David Hochman of 2500 shares of Orchestra BioMed at 4.91 subject to Rule 16b-3 | ||
David Hochman over two months ago Acquisition by David Hochman of 2000 shares of Orchestra BioMed at 4.73 subject to Rule 16b-3 | ||
David Hochman over two months ago Acquisition by David Hochman of 2500 shares of Orchestra BioMed at 4.91 subject to Rule 16b-3 | ||
David Hochman over three months ago Acquisition by David Hochman of 2500 shares of Orchestra BioMed at 5.84 subject to Rule 16b-3 |
Orchestra BioMed Management Efficiency
The company has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9166) %, meaning that it created substantial loss on money invested by shareholders. Orchestra BioMed's management efficiency ratios could be used to measure how well Orchestra BioMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to drop to -0.64. At this time, Orchestra BioMed's Other Current Assets are very stable compared to the past year. As of the 13th of December 2024, Fixed Asset Turnover is likely to grow to 1.87, while Total Assets are likely to drop about 66.7 M.Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Alexander Stadlin | Playa Hotels Resorts | 71 | |
| Philip Cooley | Biglari Holdings | 76 | |
| Hajime Uba | Kura Sushi USA | 46 | |
| Sardar Biglari | Biglari Holdings | 42 | |
| Bruce Wardinski | Playa Hotels Resorts | 64 | |
| Richard Dahl | Dine Brands Global | 69 | |
| Patrick Campbell | Herc Holdings | 68 | |
| Herbert Henkel | Herc Holdings | 70 | |
Management Performance
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 |
Orchestra BioMed Holdings Leadership Team
Elected by the shareholders, the Orchestra BioMed's board of directors comprises two types of representatives: Orchestra BioMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orchestra. The board's role is to monitor Orchestra BioMed's management team and ensure that shareholders' interests are well served. Orchestra BioMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orchestra BioMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yuval DSc, GM Therapies | ||
| George Papandreou, Senior Therapies | ||
| Avraham MD, Senior Innovation | ||
| David Hochman, Chairman Founder | ||
| Darren Sherman, President Founder | ||
| Andrew MBA, Chief Officer | ||
| HansPeter MD, Chief Officer | ||
| Inessa Wheeler, Vice Marketing | ||
| William Little, Executive Strategy | ||
| Bob Laughner, Senior Quality | ||
| Juan Lorenzo, Senior Development |
Orchestra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orchestra BioMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (16.56) % | ||||
| Current Valuation | 137.27 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Shares Owned By Insiders | 22.05 % | ||||
| Shares Owned By Institutions | 54.90 % | ||||
| Number Of Shares Shorted | 769.71 K | ||||
| Price To Book | 4.38 X | ||||
| Price To Sales | 76.83 X |
Pair Trading with Orchestra BioMed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Orchestra BioMed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orchestra BioMed will appreciate offsetting losses from the drop in the long position's value.Moving against Orchestra Stock
| 0.6 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.43 | LLY | Eli Lilly | PairCorr |
| 0.34 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Orchestra BioMed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orchestra BioMed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orchestra BioMed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orchestra BioMed Holdings to buy it.
The correlation of Orchestra BioMed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Orchestra BioMed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Orchestra BioMed Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Orchestra BioMed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.